keyword
MENU ▼
Read by QxMD icon Read
search

Mckesson

keyword
https://www.readbyqxmd.com/read/27433747/mccarthy-s-1953-compilation-a-secondary-saturation-of-mckesson-s-anesthesia-papers
#1
(no author information available yet)
No abstract text is available yet for this article.
August 2016: Anesthesiology
https://www.readbyqxmd.com/read/26655311/bloomheart-s-contact-thermometer-patent-the-mckesson-dermalor
#2
(no author information available yet)
No abstract text is available yet for this article.
December 2015: Anesthesiology
https://www.readbyqxmd.com/read/26553767/dose-delays-dose-reductions-and-relative-dose-intensity-in-patients-with-cancer-who-received-adjuvant-or-neoadjuvant-chemotherapy-in-community-oncology-practices
#3
Neelima Denduluri, Debra A Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M Favret, Phuong Khanh Morrow, Richard L Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia, Gary H Lyman
BACKGROUND: A wide variety of myelosuppressive chemotherapy regimens are used for the treatment of cancer in clinical practice. Neutropenic complications, such as febrile neutropenia, are among the most common side effects of chemotherapy, and they often necessitate delays or reductions in doses of myelosuppressive agents. Reduced relative dose intensity (RDI) may lead to poorer disease-free and overall survival. METHODS: Using the McKesson Specialty Health/US Oncology iKnowMed electronic health record database, we retrospectively identified the first course of adjuvant or neoadjuvant chemotherapy received by patients without metastases who initiated treatment between January 1, 2007, and March 31, 2011...
November 2015: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/26208445/the-effectiveness-of-tyrosine-kinase-inhibitors-and-molecular-monitoring-patterns-in-newly-diagnosed-patients-with-chronic-myeloid-leukemia-in-the-community-setting
#4
Nicholas J Di Bella, Debajyoti Bhowmik, Menaka Bhor, Mark Yap, Brooke Middlebrook, Debra Rembert, Zachary Cain, Tony Okoro, Bjorn Bolinder, Debra Patt, Elias J Jabbour
BACKGROUND: Clinical outcomes of patients with chronic myeloid leukemia (CML) treated in clinical trials, including response to therapy, may not be representative of those treated in a community setting. Thus, we sought to determine the real-world effectiveness of first-line tyrosine kinase inhibitors in CML by evaluating response rates, all-cause discontinuation, and adherence. Response monitoring patterns were also analyzed. PATIENTS AND METHODS: This retrospective observational study, using the McKesson Specialty Health/US Oncology Network (MSH/USON) iKnowMed electronic health record database and medical charts, identified newly diagnosed CML patients who received first-line imatinib, dasatinib, or nilotinib from July 2007 to March 2011, and were then followed for ≥ 18 months...
October 2015: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/25784582/improving-incidence-of-code-status-documentation-through-process-and-discipline
#5
Marcus A Neubauer, Cynthia B Taniguchi, J Russell Hoverman
Documentation of a patient's preferred code status is a critical outcome of advance care planning. Although there is agreement that code status is valuable information, little progress has been made to increase the incidence of documented code status within the medical record in an outpatient setting. Incidence of code status documentation in the community oncology setting has not been studied. In April 2013, the US Oncology Network and McKesson Specialty Health launched a new advance care planning initiative for the purpose of promoting conversations between clinicians and patients regarding end-of-life care preferences...
March 2015: Journal of Oncology Practice
https://www.readbyqxmd.com/read/25773061/clinical-outcomes-with-bevacizumab-containing-and-non-bevacizumab-containing-regimens-in-patients-with-recurrent-glioblastoma-from-us-community-practices
#6
Clara Chen, Arliene Ravelo, Elaine Yu, Rahul Dhanda, Ian Schnadig
This analysis evaluated the efficacy and safety of bevacizumab as monotherapy and with irinotecan for recurrent glioblastoma in community-based practices. Adult patients with bevacizumab-naive, recurrent glioblastoma initiating second-line treatment (July 2006-June 2010) were identified using McKesson Specialty Health/US Oncology Network health records. Overall (OS) and progression-free survival (PFS) estimates were analyzed through July 2011 and compared for bevacizumab and non-bevacizumab regimens using the log-rank test...
May 2015: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/25265841/the-aha-mckesson-quest-for-quality-prize
#7
Laura Putre
No abstract text is available yet for this article.
August 2014: Hospitals & Health Networks
https://www.readbyqxmd.com/read/25163396/dosing-patterns-toxicity-and-outcomes-in-patients-treated-with-first-line-sunitinib-for-advanced-renal-cell-carcinoma-in-community-based-practices
#8
Ian D Schnadig, Thomas E Hutson, Hsingwen Chung, Rahul Dhanda, Melissa Halm, Michael Forsyth, Nicholas J Vogelzang
BACKGROUND: This retrospective study by McKesson Specialty Health (MSH)/US Oncology Network (USON) evaluates dosing patterns of first-line sunitinib for patients with advanced renal cell carcinoma (aRCC) and its association with toxicities and clinical outcomes in community practices. PATIENTS AND METHODS: Patients with aRCC who started first-line sunitinib between June 1, 2007, and May 31, 2011, were identified from 17 MSH/USON practices. Clinical data were extracted from iKnowMed electronic medical records linked to the MSH/USON pharmacy database...
December 2014: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/25046968/improving-patient-access-and-streamlining-processes-through-enterprise-intelligence-systems
#9
Ronald L Dunn
This article demonstrates how enterprise intelligence systems can be used to improve operational efficiency in hospitals. Enterprise intelligence systems mine raw data from disparate systems and transform the data into actionable information, which when used appropriately, support streamlined processes, optimize resources, and positively affect staff efficiency and the quality of patient care. Case studies on the implementation of McKesson Performance Visibility and Capacity Planner enterprise intelligence solutions at the Southlake Regional Health Centre and Lions Gate and Richmond Hospitals are provided...
2014: Healthcare Management Forum
https://www.readbyqxmd.com/read/24443735/opening-the-black-box-the-impact-of-an-oncology-management-program-consisting-of-level-i-pathways-and-an-outbound-nurse-call-system
#10
J Russell Hoverman, Ira Klein, Debra W Harrison, Jad E Hayes, Jody S Garey, Robyn Harrell, Maria Sipala, Scott Houldin, Melissa D Jameson, Mitra Abdullahpour, Jessica McQueen, Greg Nelson, Diana K Verrilli, Marcus Neubauer
PURPOSE: The Innovent Oncology Program aims to improve the value of cancer care delivered to patients. McKesson Specialty Health and Texas Oncology (TXO) collaborated with Aetna to launch a pilot program. The study objectives were to evaluate the impact of Innovent on Level I Pathway compliance, implement the Patient Support Services program, and measure the rate and costs associated with chemotherapy-related emergency room (ER) visits and hospital admissions. PATIENTS AND METHODS: This was a prospective, nonrandomized evaluation of patients enrolled in Innovent from June 1, 2010, through May 31, 2012...
January 2014: Journal of Oncology Practice
https://www.readbyqxmd.com/read/24337922/medical-ipad-use-in-the-cardiac-catheterization-and-echo-laboratories
#11
COMPARATIVE STUDY
Ifat Lavi, Guy Malki, Ran Kornowski
The present study aims to describe a dedicated cardiac imaging application on a tablet and to assess the accuracy and reproducibility of this novel application for measurement on angiography and echocardiography data sets. Tablet devices have recently been used in radiological image interpretation and enable transfer of images. It allows the clinician to look up clinical information, search the Internet and communicate with colleagues and family. The study group consisted of 30 patients who had both echocardiographic and angiographic examinations...
February 2014: International Journal of Cardiovascular Imaging
https://www.readbyqxmd.com/read/24240548/the-accuracy-of-interqual-criteria-in-determining-the-need-for-observation-versus-hospitalization-in-emergency-department-patients-with-chronic-heart-failure
#12
Hao Wang, Richard D Robinson, Marco Coppola, David Fernandez, Ferran Ros, Nestor R Zenarosa, Mandy J Burton, Kathleen A Delaney
McKesson's Interqual criteria are one of the medical screening criteria that are widely used in emergency departments (EDs) to determine if patients qualify for observation or inpatient admission. Chronic heart failure (CHF) is one of the most common yet severe cardiovascular diseases seen in the ED with a relatively higher admission rate. This study is to evaluate the accuracy of Interqual criteria in determining observation versus hospitalization need in CHF patients. From January 2009 till December 2010, data from 503 CHF patients were reviewed...
December 2013: Critical Pathways in Cardiology
https://www.readbyqxmd.com/read/24219900/a-survey-of-trauma-database-utilisation-in-england
#13
MULTICENTER STUDY
M Racy, S Al-Nammari, C B Hing
Trauma registries are used worldwide to coordinate patient care as well as provide data for audit and research purposes. National registries collect this data, producing research opportunities, outcome standards and a means by which to benchmark trauma centre performance. The Trauma Audit and Research Network (TARN) is the UK national registry, with data upload being mandatory from all major trauma centres (MTCs), a process which is manual and time and resource intensive. A telephone survey was carried out to collect data from all 26 MTCs in England...
March 2014: Injury
https://www.readbyqxmd.com/read/24020171/the-aha-mckesson-quest-for-quality-prize
#14
Paul Barr
No abstract text is available yet for this article.
August 2013: Hospitals & Health Networks
https://www.readbyqxmd.com/read/23942918/evaluating-use-characteristics-for-the-oncotype-dx-21-gene-recurrence-score-and-concordance-with-chemotherapy-use-in-early-stage-breast-cancer
#15
Clara Chen, Rahul Dhanda, Wan-Yu Tseng, Michael Forsyth, Debra A Patt
PURPOSE: Oncotype Dx 21-gene assay recurrence score (RS) predicts recurrence of early-stage breast cancer (ESBC). We investigated whether patient, tumor, or practice characteristics drive its use and explored Oncotype DX RS and chemotherapy use in subgroups. METHODS: Patients with ESBC with documented estrogen receptor-positive, lymph node-negative, human epidermal growth factor receptor 2-negative tumors registered within McKesson Specialty Health's iKnowMed electronic health record were included...
July 2013: Journal of Oncology Practice
https://www.readbyqxmd.com/read/23730494/demographics-treatment-patterns-safety-and-real-world-effectiveness-in-patients-aged-70-years-and-over-with-chronic-lymphocytic-leukemia-receiving-bendamustine-with-or-without-rituximab-a-retrospective-study
#16
Kathryn S Kolibaba, James A Sterchele, Avani D Joshi, Michael Forsyth, Erin Alwon, Hooman Beygi, Gerard T Kennealey
OBJECTIVES: Bendamustine is a unique cytotoxic agent active against various human malignancies, including chronic lymphocytic leukemia (CLL). In vitro studies suggest that cytotoxic activity of bendamustine on CLL-derived cells is synergized by rituximab. A retrospective chart review was conducted to characterize treatment-naïve outpatients and those with relapsed disease aged 70 years and over with CLL receiving bendamustine (with or without rituximab) and to evaluate real-world patterns of care, safety, and effectiveness...
June 2013: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/23513962/poor-interoperability-of-the-adams-harbertson-method-for-analysis-of-anthocyanins-comparison-with-aoac-ph-differential-method
#17
COMPARATIVE STUDY
Larry M Brooks, Benjamin J Kuhlman, Doug W McKesson, Leo McCloskey
The poor interoperability of anthocyanin glycosides measurements by two pH differential methods is documented. Adams-Harbertson, which was proposed for commercial winemaking, was compared to AOAC Official Method 2005.02 for wine. California bottled wines (Pinot Noir, Merlot, and Cabernet Sauvignon) were assayed in a collaborative study (n=105), which found mean precision of Adams-Harbertson winery versus reference measurements to be 77 +/- 20%. Maximum error is expected to be 48% for Pinot Noir, 42% for Merlot, and 34% for Cabernet Sauvignon from reproducibility RSD...
January 2013: Journal of AOAC International
https://www.readbyqxmd.com/read/23227669/economies-of-scale-deal-will-let-mckesson-expand-distribution-to-docs
#18
Paul Barr
No abstract text is available yet for this article.
October 29, 2012: Modern Healthcare
https://www.readbyqxmd.com/read/22667036/mckesson-settling-up-190-million-payment-latest-in-drug-price-flap
#19
Joe Carlson
No abstract text is available yet for this article.
April 30, 2012: Modern Healthcare
https://www.readbyqxmd.com/read/22663214/foremost-mckesson-research-center
#20
(no author information available yet)
No abstract text is available yet for this article.
January 1, 1982: Environmental Science & Technology
keyword
keyword
117692
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"